I

Iatros International | Bloemfontein, South Africa

Research site
(Unclaimed)
Location
20 Captain Proctor Street, Brandwag, Bloemfontein, Free State, South Africa
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

16 of 35
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Semaglutide
Drug: Placebo (semaglutide)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer's Disease
Drug: Semagludtide
Drug: Placebo (semaglutide)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of en...

Active, not recruiting
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Drug: LHRH Agonist
Drug: Fulvestrant or an Aromatase Inhibitor (Physician Choice)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in...

Active, not recruiting
Chronic Inducible Urticaria
Biological: barzolvolimab
Drug: Matching Placebo

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Enrolling
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depr...

Active, not recruiting
Depressive Disorder, Major
Drug: Placebo
Drug: Seltorexant

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COP...

Enrolling
Chronic Obstructive Pulmonary Disease (COPD)
Drug: Placebo
Drug: Astegolimab

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Obicetrapib

This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the eff...

Active, not recruiting
Chronic Kidney Diseases
Drug: KBP-5074
Drug: Placebo

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial conditions

Cardiovascular Diseases (4 trials)
Alzheimer Disease (3 trials)
Chronic Renal Insufficie... (3 trials)
Inflammation (3 trials)
Kidney Diseases (3 trials)
Arthritis (2 trials)
Breast Cancer (2 trials)
Depression (2 trials)
Heart Failure (2 trials)
Human Influenza (2 trials)

And 39 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems